SCHEMBL23755478

SCHEMBL23755478

CCOC(=O)c1cc2cc(F)cc(C3=CCN(C(=O)OC(C)(C)C)CC3)c2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK9 P50750 4/20 0.44
▸ CCNT1 O60563 1/20 0.44
▸ JAK1 P23458 1/20 0.44
▸ PDK4 Q16654 1/20 0.43
▸ GRM5 P41594 7/20 0.42
▸ GRM1 Q13255 7/20 0.42
▸ CNR1 P21554 1/20 0.41
▸ ELANE P08246 1/20 0.41
▸ HTR6 P50406 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ GABRP O00591 1/20 0.39
▸ GABRD O14764 1/20 0.39
▸ GABRA1 P14867 1/20 0.39
▸ GABRB1 P18505 1/20 0.39
▸ GABRG2 P18507 1/20 0.39
▸ GABRB3 P28472 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRA3 P34903 1/20 0.39
▸ GABRA2 P47869 1/20 0.39
▸ GABRB2 P47870 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29942132 1.00 CDK9 (0.44) CDK9CCNT1JAK1PDK4GRM5
SCHEMBL30122394 0.89 CDK9 (0.38) CDK9CCNT1JAK1PDK4GRM5
SCHEMBL29942289 0.87 PDK4 (0.52) CDK9CCNT1JAK1PDK4GRM5
SCHEMBL23756013 0.87 PDK4 (0.52) CDK9CCNT1JAK1PDK4GRM5
SCHEMBL29942167 0.80 PDE10A (0.46) CDK9CCNT1JAK1PDK4GRM5
SCHEMBL23756602 0.80 PDE10A (0.46) CDK9CCNT1JAK1PDK4GRM5
SCHEMBL18331902 0.80 TNF (0.43) CDK9CCNT1JAK1PDK4GRM5
SCHEMBL17109184 0.80 KDM4E (0.52) JAK1CNR1KDM4EALDH1A1HPGD
SCHEMBL18332138 0.79 PDK4 (0.42) CDK9CCNT1JAK1PDK4GRM5
SCHEMBL23755573 0.77 ALDH1A1 (0.44) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4103559-B1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2026-03-04 — — EP disclosed
US-12473304-B2 Heterocyclic PAD4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-11-18 — — US disclosed
US-20230167131-A1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-06-01 — — US disclosed
US-20230167131-A1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-06-01 — — US disclosed
US-20230167131-A1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-06-01 — — US disclosed
EP-4103559-A1 HETEROCYCLIC PAD4 INHIBITORS Bristol-Myers Squibb Company (US) 2022-12-21 — — EP disclosed
CN-115348961-A Heterocyclic PAD4 inhibitors 百时美施贵宝公司 2022-11-15 — — CN disclosed
WO-2021163254-A1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-08-19 — — WO disclosed
WO-2021163254-A1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473304-B2 Heterocyclic PAD4 inhibitors PADI6, PADI4, PADI1 CDK9 905/4885CCNT1 1172/4885JAK1 708/4885
US-20230167131-A1 HETEROCYCLIC PAD4 INHIBITORS PADI4, PADI2, PADI6 CDK9 784/4885CCNT1 3302/4885JAK1 742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback